Literature DB >> 16228808

Infrapopliteal angioplasty for limb salvage in the setting of renal failure: do results justify its use?

Bernadette Aulivola1, Mauro Gargiulo, Marco Bessoni, Antonio Rumolo, Andrea Stella.   

Abstract

Multiple reports advocate the use of infrapopliteal angioplasty for limb salvage; however, its utility in the setting of renal failure is unclear. We performed angioplasty, rather than bypass, for tibial stenoses or occlusions <3 cm on 90 limbs of 79 patients (64.4% male, mean age 67.2 years), all with ischemic ulcer. Seventy (77.8%) had diabetes mellitus and 16 (17.8%) had end-stage renal disease (ESRD). Mean follow-up was 14.3 months (range 0.3-45). Associated femoropopliteal revascularization was required in 28 (31.0%) limbs. Primary angiographic success was achieved in 83 (92.2%) limbs. Residual stenosis or thrombosis occurred in two and five limbs, respectively. Dissection occurred in six limbs, all successfully treated with stent placement. Ulcer healing occurred after initial angioplasty in 41 (55.4%) non-ESRD and four (25%) ESRD limbs. Subsequent revascularization procedures were required in 21 (23.3%) limbs, including six bypasses and 15 repeat angioplasties, of which three underwent subsequent bypasses. Major amputation was required in 11 (14.9%) non-ESRD and seven (43.7%) ESRD limbs. Limb salvage was 84.4% and 80.2% in those without and 52.5% and 52.5% in those with ESRD at 1 and 3 years, respectively (p = 0.01). Thirty-day mortality was 2.2%. Overall actuarial survival was 82.2% and 62.1% at 1 and 3 years, respectively, and did not differ significantly between patients with and without ESRD (p = 0.66). Infrapopliteal angioplasty is a safe technique with low procedural morbidity and mortality. However, the inferior wound-healing and limb-salvage rates observed in patients with renal failure bring to question the utility of infrapopliteal angioplasty in this population.

Entities:  

Mesh:

Year:  2005        PMID: 16228808     DOI: 10.1007/s10016-005-7970-6

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  7 in total

1.  Cost-effectiveness of revascularization for limb preservation in patients with end-stage renal disease.

Authors:  Neal R Barshes; Panos Kougias; C Keith Ozaki; Philip P Goodney; Michael Belkin
Journal:  J Vasc Surg       Date:  2014-03-20       Impact factor: 4.268

2.  Management of critical lower limb ischemia in endovascular era: experience from 511 patients.

Authors:  Baker Ghoneim; Hussein Elwan; Waleed Eldaly; Hussein Khairy; Ahmad Taha; Amr Gad
Journal:  Int J Angiol       Date:  2014-09

3.  Diabetic foot wounds in haemodialysis patients: 2-year outcome after percutaneous transluminal angioplasty and minor amputation.

Authors:  Kyoichi Matsuzaki; Akira Miyamoto; Naohiro Hakamata; Masahiro Fukuda; Yasutaka Yamauchi; Takako Akita; Ryoji Kuhara; Shingo Tezuka
Journal:  Int Wound J       Date:  2012-10-24       Impact factor: 3.315

4.  Diabetic foot infections in the elderly: primary amputation versus 'foot-sparing surgery'. A case report.

Authors:  Luis R Leon; Shemuel B Psalms; Jodi Walters
Journal:  Int Wound J       Date:  2007-12       Impact factor: 3.315

5.  Recurrence of Critical Limb Ischemia After Endovascular Intervention in Patients with Diabetic Foot Ulcers.

Authors:  Marco Meloni; Valentina Izzo; Laura Giurato; Costantino Del Giudice; Valerio Da Ros; Valerio Cervelli; Roberto Gandini; Luigi Uccioli
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-06-01       Impact factor: 4.730

6.  Rate of Ipsilateral Chronic Limb-Threatening Ischemia (CLTI) After Kidney Transplantation: A Retrospective Single-Center Study.

Authors:  Abdul Kader Natour; Ziad Al Adas; Timothy Nypaver; Alexander Shepard; Mitchell Weaver; Lauren Malinzak; Anita Patel; Loay Kabbani
Journal:  Cureus       Date:  2022-05-29

Review 7.  The Importance of Patency in Patients with Critical Limb Ischemia Undergoing Endovascular Revascularization for Infrapopliteal Arterial Disease.

Authors:  Frederic Baumann; Christoph Ozdoba; Ernst Gröchenig; Nicolas Diehm
Journal:  Front Cardiovasc Med       Date:  2015-01-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.